Presentation is loading. Please wait.

Presentation is loading. Please wait.

by Michael F. Leahy, and J. Harvey Turner

Published byLillian Jennings Modified over 5 years ago

Similar presentations

Presentation on theme: "by Michael F. Leahy, and J. Harvey Turner"— Presentation transcript:

1 by Michael F. Leahy, and J. Harvey Turner
Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients by Michael F. Leahy, and J. Harvey Turner Blood Volume 117(1):45-52 January 6, 2011 ©2011 by American Society of Hematology

2 Kaplan-Meier plots of overall survival (OS) and progression-free survival (PFS) in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. Kaplan-Meier plots of overall survival (OS) and progression-free survival (PFS) in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. Michael F. Leahy, and J. Harvey Turner Blood 2011;117:45-52 ©2011 by American Society of Hematology

3 Kaplan-Meier plots of PFS by response in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. Kaplan-Meier plots of PFS by response in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. CR/CRu indicates complete response; PR, partial response; and NR, no response. Michael F. Leahy, and J. Harvey Turner Blood 2011;117:45-52 ©2011 by American Society of Hematology

4 Kaplan-Meier plots of survival by remission status in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. Kaplan-Meier plots of survival by remission status in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. CR/CRu indicates complete response; PR, partial response; and NR, no response. Michael F. Leahy, and J. Harvey Turner Blood 2011;117:45-52 ©2011 by American Society of Hematology

Download ppt "by Michael F. Leahy, and J. Harvey Turner"

Similar presentations

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970–1979 1974: FDA approves doxorubicin, a vital part of combination chemotherapy.

Progress Against Lymphoma. 1970–1979 Progress Against Lymphoma 1970– : FDA approves doxorubicin, a vital part of combination chemotherapy.
Treatment of early-stage Hodgkin lymphoma

Treatment of early-stage Hodgkin lymphoma
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.
by Timothy P. Hughes, and David M. Ross

by Timothy P. Hughes, and David M. Ross
by James O. Armitage, and Dan L. Longo

by James O. Armitage, and Dan L. Longo
A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11):3909-3918 June 1, 1997 ©1997.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.
Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.

Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose by Wolfgang Römer, Axel-R. Hanauske, Sibylle.
Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome by Kerry J.
Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,
Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.
Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse.

Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse.
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

Similar presentations

Ads by Google